Press Releases - 2023-08-01
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-300
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
Press Releases - 2023-06-21
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-300
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
Press Releases - 2023-05-23
PureTech Founded Entity Sonde Health Announces Respiratory Responsive Vocal Biomarker Tool Differentiates Patients with Respiratory Conditions from Healthy Individuals
Press Releases - 2023-05-09
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
Press Releases - 2023-05-04
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
Press Releases - 2023-04-28
PureTech Announces Annual Results for Year Ended December 31, 2022
Press Releases - 2023-04-25
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies